K-State’s canine comfort breakthrough
Dogs experience pain just like humans, and a groundbreaking solution is now on the horizon. In collaboration with research partners, Kansas State University’s College of Veterinary Medicine team has patented a new formula to alleviate moderate to severe pain in our furry friends.
Led by Butch KuKanich, professor of pharmacology, alongside Kate KuKanich, professor of small animal internal medicine, and David Rankin, clinical professor and head of veterinary anesthesiology, the team has developed an innovative blend of the opioid methadone and other compounds to provide superior pain relief for dogs. One ingredient is naltrexone, which helps deter opioid abuse, misuse or diversion by humans.
“This oral opioid formulation ensures consistent clinical analgesia in postoperative dogs within an hour, with the added benefit of deterring opioid misuse by humans,” said Butch KuKanich.
The formulation, a result of years of research, simplifies pain management for dogs, requiring only two daily doses. A long-acting injectable version has also been devised for situations where oral administration isn’t feasible.
“This breakthrough addresses a significant gap in canine pain management,” Rankin said.
Until now, treatment options for canine pain have been limited, with nonsteroidal anti-inflammatory drugs (NSAIDs) offering only partial relief and carrying potential adverse effects.
The breakthrough discovery by the K-State team not only promises effective pain relief for dogs but also holds the potential to mitigate opioid abuse, marking a significant advancement in compassionate care for our furry companions.
Support the faculty and College of Veterinary Medicine in their quest to make tails wag again. Join us in bringing this revolutionary pain relief to dogs in need.
Written by: Lilly Majors
Curated from: College of Veterinary Medicine researchers receive patent for canine pain relief formulation (k-state.edu)
